The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 30, 2017

Filed:

May. 14, 2013
Applicant:

Cancer Research Technology Limited, London Greater London, GB;

Inventors:

Ian Collins, Sutton, GB;

Thomas Peter Matthews, Sutton, GB;

Tatiana Faria Da Fonseca Mchardy, Sutton, GB;

James Osborne, Saffron Walden, GB;

Michael Lainchbury, Harlow, GB;

Michael Ian Walton, Sutton, GB;

Michelle Dawn Garrett, Sutton, GB;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 413/14 (2006.01); C07D 401/12 (2006.01); A61K 9/00 (2006.01); A61K 31/4745 (2006.01); A61K 31/5377 (2006.01); A61K 31/7068 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 413/14 (2013.01); A61K 9/0053 (2013.01); A61K 31/4745 (2013.01); A61K 31/5377 (2013.01); A61K 31/7068 (2013.01); A61K 45/06 (2013.01); C07D 401/12 (2013.01);
Abstract

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to herein as 'TFM compounds') which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionizing radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; or (h) an inhibitor of a DNA damage repair enzyme.


Find Patent Forward Citations

Loading…